Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.
Article CAS PubMed PubMed Central Google Scholar
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Article CAS PubMed PubMed Central Google Scholar
Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429–34.
Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.
Article PubMed PubMed Central Google Scholar
Schaefer L, Comfere N, Sokumbi O. Development of cutaneous t-cell lymphoma following biologic treatment: a systematic review. Am J Clin Dermatol. 2023;24:153–64.
Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7:61.
Wang X, Wang W, Vega F, Quesada AE. Aggressive mediastinal lymphomas. Semin Diagn Pathol. 2024;41:125–39.
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.
Article CAS PubMed PubMed Central Google Scholar
Patel RP, Ghilardi G, Porazzi P, Yang S, Qian D, Pajarillo R, et al. Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5 + nodal T-cell lymphomas. Blood. 2022;140:1604–5.
Raikar SS, Fleischer LC, Moot R, Fedanov A, Paik NY, Knight KA, et al. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. Oncoimmunology. 2018;7:e1407898.
Angelos MG, Patel RP, Ruella M, Barta SK. Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies. Transpl Cell Ther. 2024;30:171–86.
Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–92.
Article CAS PubMed PubMed Central Google Scholar
Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, et al. Reversible transgene expression reduces fratricide and permits 4-1bb costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6:47–58.
Article CAS PubMed Google Scholar
Hill L, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, et al. CD5 CAR T-cells for treatment of patients with relapsed/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity. Biol Blood Marrow Transpl. 2020;26:S237.
Feng J, Xu H, Cinquina A, Wu Z, Chen Q, Zhang P, et al. Treatment of aggressive t cell lymphoblastic lymphoma/leukemia using anti-CD5 CAR T cells. Stem Cell Rev Rep. 2021;17:652–61.
Article CAS PubMed PubMed Central Google Scholar
Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, et al. Single-cell transcriptomics reveals immune reconstitution in patients with R/R T-ALL/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res. 2023;29:1484–95.
Article CAS PubMed Google Scholar
Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2022;28:2830–43.
Article CAS PubMed Google Scholar
Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321–34.
You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9:64–78.
CAS PubMed PubMed Central Google Scholar
Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285–96.
Article CAS PubMed PubMed Central Google Scholar
Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23:1416–23.
Article CAS PubMed Google Scholar
Onuoha S, Ferrari M, Bulek A, Bughda R, Manzoor S, Srivastava S, et al. Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas. Blood. 2018;132:1661.
Zhang C, Palashati H, Rong Z, Lin N, Shen L, Liu Y, et al. Pre-depletion of TRBC1 + T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. Mol Cancer. 2020;19:162.
Article CAS PubMed PubMed Central Google Scholar
Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY. An off-the-shelf CD2 universal CAR-T therapy for T-cell malignancies. Leukemia. 2023;37:2448–56.
Article CAS PubMed PubMed Central Google Scholar
Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3:e99442.
Article PubMed PubMed Central Google Scholar
Cárdenas RMV, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, et al. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023;24:2135–49.
Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655–62.
Article CAS PubMed Google Scholar
Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2017;8:112783–96.
Article PubMed PubMed Central Google Scholar
Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-cell leukemia/lymphoma. Int J Mol Sci. 2023;24:8731.
Article CAS PubMed PubMed Central Google Scholar
Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017;52:243–53.
Article CAS PubMed PubMed Central Google Scholar
Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 2022;29:167–77.
留言 (0)